The pipeline that Biocon sits on is actually unique on a global platform and Mylan’s backing the way, they have been able to do things in Europe, said Prakash Diwan, Market Expert.

"Biocon’s expertise in developing biologics, will definitely want to put this company in a very different P/E growth multiple. The only thing is I want to caution people is that don’t think we are going to buy it today,” said Diwan.

The flow of news is always want to keep Biocon into positive disposition, so buy it on dips, keep on adding it to the portfolio, he added.